PARP inhibitor combination therapy.
View/ Open
Date
2016-12-01Author
Dréan, A
Lord, CJ
Ashworth, A
Type
Journal Article
Metadata
Show full item recordAbstract
In 2014, olaparib (Lynparza) became the first PARP (Poly(ADP-ribose) polymerase) inhibitor to be approved for the treatment of cancer. When used as single agents, PARP inhibitors can selectively target tumour cells with BRCA1 or BRCA2 tumour suppressor gene mutations through synthetic lethality. However, PARP inhibition also shows considerable promise when used together with other therapeutic agents. Here, we summarise both the pre-clinical and clinical evidence for the utility of such combinations and discuss the future prospects and challenges for PARP inhibitor combinatorial therapies.
Collections
Subject
Animals
Humans
Neoplasms
Poly(ADP-ribose) Polymerases
Drug Combinations
Immunotherapy
Poly(ADP-ribose) Polymerase Inhibitors
Research team
Gene Function
Language
eng
Date accepted
2016-10-26
License start date
2016-12
Citation
Critical reviews in oncology/hematology, 2016, 108 pp. 73 - 85
Publisher
ELSEVIER SCIENCE INC